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Abstract
Objective—To determine if SMAD4 expression is associated with recurrence pattern after
resection for pancreatic ductal adenocarcinoma (PDA)
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Introduction—SMAD4 expression status has been reported to be associated with patterns of
failure in PDA, but studies have not examined recurrence patterns after resection.
Methods—A tissue microarray was constructed including 127 patients with resected PDA and
either short (<12 months) or long (>30 months) survival. SMAD4 expression was evaluated by
immunohistochemistry and categorized as present or lost in tumor cells. Conventional pathologic
features (lymph node metastases, positive resection margin, poor grade, tumor size) were
recorded, and disease-specific outcomes (e.g. recurrence pattern and early cancer-specific
mortality) determined.

Author Manuscript

Results—Loss of SMAD4 expression in pancreatic adenocarcinoma was identified in 40 of 127
patients (32 %). SMAD4 loss occurred in 27% of patients who experienced isolated local
recurrence, 33% of patients with a distant recurrence, 33% of patients who recurred locally and at
distant sites, and 25% of patients who were without evidence of recurrence (Fisher's exact, p=0.9).
In a multivariate analysis, the presence of regional lymph node metastases was the only factor
associated with the development of distant metastases (odds ratio, OR=4.7, p=0.02). SMAD4 was
neither associated with recurrence pattern (OR=0.9, p=0.9), nor early death (OR=0.5, p=0.15).
Conclusion—Primary tumor SMAD4 expression status was not a predictor of recurrence pattern
in a large cohort of patients with resected PDA.

Corresponding author: Peter J. Allen, MSKCC. Department of Surgery Hepatopancreatobiliary Service 444 E 68th St Mailbox 328
New York, NY 10065 Fax: (212) 717-3645 Phone: (212) 639-5132.
*indicates co-first author and performed equal amount of work in the project
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Introduction
The management approach for pancreatic ductal adenocarcinoma has not changed
significantly over the past two decades, aside from more frequent use of neoadjuvant
treatment at some centers[1] and the use of the multi-drug regimen FOLFIRINOX (5fluorouracil, leucovorin, irinotecan, and oxaliplatin) in good performance status patients
with advanced disease [2]. Most patients are treated similarly using an empiric gemcitabinebased approach, despite the fact that pancreatic adenocarcinoma is a heterogeneous disease
with significant molecular differences between tumors [3]. In the modern era of molecular
profiling, there has been a push to identify molecular signatures that could be used to predict
tumor biology, and perhaps tailor treatment [4-8].
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In this context, two intriguing studies have recently been published which suggest that the
SMAD4 expression pattern in pancreatic cancer is associated with disease distribution and
eventual pattern of failure [9, 10]. One study analyzed SMAD4 expression patterns in
pancreatic cancer in autopsies [10], and a second study focused on patients with locally
advanced disease [9]. The studies reached similar conclusions in two distinct patient
populations- that SMAD4 protein expression was associated with a locally predominant
progression pattern (with treatment implications for local therapies such as radiation) while
loss of SMAD4 was associated with distant metastases (with adjuvant radiation less likely to
impact outcome). Validation in patients with resectable pancreatic cancer would support a
treatment paradigm based on SMAD4 expression status, where chemoradiation would be
favored in patients harboring tumors with retained SMAD4 expression. On the other hand,
patients with absent SMAD4 expression would be reasonably spared the toxic effects of
such treatment. In this study, we assessed the utility of SMAD4 expression status as a
biomarker of recurrence pattern in a large cohort of patients with resectable pancreatic
cancer.

Author Manuscript

Methods
Patients
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This study was approved by the Memorial Sloan-Kettering Cancer Center (MSKCC)
institution review board. Patients underwent a pancreaticoduodenectomy or a distal
pancreatectomy for ductal adenocarcinoma at MSKCC after the year 2000. Patients were
selected based on survival, and included if they suffered a cancer-specific death within 1
year of resection (short survivors) or survived at least 30 months (long survivors). The TMA
was constructed as part of a separate study of prognostic factors (manuscript in submission).
As described elsewhere, survival cutoffs were selected to achieve a time gap between study
groups (>18 months) that adequately distinguished aggressive and less aggressive tumor
biology, and still yielded sample sizes with sufficient power for statistical analyses. In the
present study, the study design which included dichotomous groups based on survival
enabled comparisons of SMAD4 expression at two ends of the biological spectrum; the
more aggressive variety has a biological phenotype that more closely approximates the
phenotypes of PDAs included in the two aforementioned studies of SMAD4 in advanced
pancreatic cancer [9, 10].
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Clinicopathologic Information
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Clinicopathologic data were extracted from the prospectively maintained MSKCC
Pancreatic Surgery Database and from review of electronic medical records. Collected
pathologic variables included resection margin status, lymph node status, tumor size, and
histologic grade. Clinical information included recurrence pattern and the use of adjuvant
chemotherapy or radiation. The recurrence pattern was determined through careful
examination of medical records and follow-up imaging. Both synchronous and
metachronous sites of recurrence were recorded. A local recurrence was defined as a
retroperitoneal recurrence that occurred either in the resection bed or in the retroperitoneal
lymph nodes. A distant recurrence was defined as recurrence at any other site, such as in the
peritoneum, liver, lungs, or other solid organ. For patients who had not reached the endpoint
of death, the pattern of failure at the time of the last patient encounter was recorded.

Author Manuscript

Tissue Preparation
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Immunohistochemical Analysis

A tissue microarray (TMA) was constructed from tissue cores obtained from formalin-fixed,
paraffin-embedded tissue blocks in 151 patient samples. A single representative block was
selected from each patient, and areas with the highest tumor density on a corresponding H &
E stained section were marked under the microscope. TMA's were then constructed on an
automated tissue array machine (ATA-27, Beecher Instruments, Silver Spring, MD).
Triplicate cores of 0.6 mm in diameter were punched from each block and transferred to a
virgin TMA block. Cores were placed on the block in no particular order so that
immunohistochemical review of stained TMA slides could be performed in an unbiased
fashion. Four micron thick sections were prepared from the TMA blocks for H & E stains
and used for SMAD4 immunohistochemistry.

Immunohistochemical stains were performed using a standard streptavidin-biotinperoxidase
procedure. Thin 4 μm paraffin sections were deparaffinized and hydrated with distilled
water. Heat-induced epitope retrieval with citric acid buffer (pH 6, 30 minutes, at 97°C) was
performed with a steamer. Slides were cooled to 60°C and washed in running water for 2
minutes, and transferred to PBS buffer. A primary antibody against SMAD4 (1:800, Santa
Cruz Bio, Santa Cruz, CA) was applied overnight at 4°C. The slides were washed with PBS,
followed by a secondary antibody (1:500, biotinylated anti-mouse, Vector Labs,
Burlingame, CA) for 60 minutes at room temperature. After additional washing, the slides
were incubated for 60 minutes with streptavidin, washed, and developed with DAB for 5
minutes. The slides were washed and counterstained with Harris hematoxylin.

Author Manuscript

Immunohistochemical review was performed by a senior pancreatic pathologist (L.H.T.). A
second pathologist scored the TMAs to test for inter-rater reliability (W.L.). Pancreatic
ductal adenocarcinomas were considered to have absent SMAD4 expression if neoplastic
cells lacked immunohistochemical labeling but non-neoplastic cells (e.g. stromal cells)
reacted positively as an internal control [9, 10]. Any convincing labeling was considered as
positive for individual cores, and the predominant SMAD4 expression pattern in each
triplicate set was recorded for analysis. Representative cores labeled with an antibody to
SMAD4 are provided in Figure 1.
Ann Surg. Author manuscript; available in PMC 2015 May 14.
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Statistical Analysis
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The analysis was performed using Intercooled Stata 8.2. Categorical variables were tested
by the Fisher's exact test in the univariate analysis, and with logistic regression in the
multivariate analysis. Inter-rater agreement of SMAD4 immunohistochemistry was assessed
with the kappa statistic, and interpreted according to the following scale: κ<0 shows poor
agreement, 0 to 0.20 shows slight agreement, 0.21 to 0.40 shows fair agreement, 0.41 to 0.60
shows moderate agreement, 0.61-0.80 shows substantial agreement, and >0.80 shows almost
perfect agreement [11]. All statistics were two-tailed with a p value<0.05 indicating
statistical significance.

Results
Author Manuscript

The TMA included 151 different patient samples. There was insufficient neoplastic
cellularity for proper assessment of SMAD4 expression in 9 sample sets and the recurrence
pattern could not be determined using available follow-up documentation in 15 patients. The
final analysis therefore included 127 patients, including 110 right sided lesions and 17 left
sided lesions. The specimens were analyzed in aggregate, as well as in subgroups stratified
by survival after resection (i.e. short and long survivors). A total of 56 patients had a short
cancer-specific survival after resection (survival<12 months) and 71 patients had a relatively
long survival (survival>30 months). The endpoint of death occurred in 112 of the 127
patients (88%). Median follow-up in living patients was 48 months (range 31-108 months).

Author Manuscript

Patients were grouped into one of four categories based on their recurrence pattern. The
distribution of patients by recurrence pattern is provided in Table 1; the data are presented
for the total cohort, as well as each survival group. Recurrence patterns for the total cohort
were as follows: local recurrence only (n=15, 12%), distant recurrence only (n=42, 33%),
both local and distant recurrence (n=58, 46%), and no recurrence (n=12, 9%). The majority
of patients failed outside of the retroperitoneum (n=100, 79%). Out of these patients, just
over half (n=58, 58%) developed a local recurrence in addition to a distant metastasis.
Virtually all of the patients who recurred locally in the retroperitoneum without distant
failure (i.e. local recurrence only) had tumors with a relatively favorable biology (13 out of
15 patients were in the long survival group). Patients with distant recurrences are more or
less equally divided between the short and long survivor groups, regardless of whether or
not a local recurrence was also present.
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With regards to specific organ sites of recurrence, 73 of 127 patients (57%) had a
retroperitoneal recurrence, 66 (52%) recurred in the liver, 44 (35%) elsewhere in the
peritoneum, and 19 (15%) in the lung. Less common sites of metastases included the brain,
bone, spine, soft tissue, adrenal gland, salivary gland, and tongue (Figure 2). Roughly half of
the patients were noted to have recurred at multiple sites (n=62, 49%), and twelve patients
(9%) had not experienced disease recurrence. At last follow-up, 9 of the 12 patients without
disease remained alive with a median follow up of 60 months (range, 31-108 months). Of
note, patients who died an early cancer-specific death recurred more frequently in the liver
than patients with a prolonged survival (75% vs. 34%, p<0.0001). In contrast, lung
metastases were more common in long-term survivors (21% vs. 7%, p=0.04).
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Next, we examined whether or not an association existed between SMAD4 expression and
the pattern of failure (Table 2). Loss of SMAD4 expression in the tumor was observed in
32% of the total cohort, and ranged between 25% and 33% for each recurrence category
(p=0.9). When the subgroup of patients with the most biologically aggressive tumors was
examined (the short survivors share a similar aggressive phenotype with many patients in
prior studies of SMAD4 and recurrence with advanced PDA), no difference amongst the
recurrence patterns was observed (p=1.0, data not shown). Additionally, we analyzed the
data according to anatomic or organ-specific site of metastasis (Figure 2). Since many
patients recurred at multiple sites and therefore are included in multiple organ-specific
subgroups, the data were not evaluated statistically. Loss of SMAD4 across the four most
common metastatic sites were as follows: retroperitoneum, 32%; liver, 35%; peritoneum,
32%; and lung, 32%. With regards to primary tumor location, loss of SMAD4 was observed
in 30% of right sided lesions and 41% of left sided lesions (p=0.2).
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A multivariate analysis was performed to evaluate SMAD4 as a predictor of recurrence
pattern after adjusting for conventional pathologic features and adjuvant treatment data.
Only patients with documented recurrences were included in the subgroup analysis, and
patients without any evidence of disease (n=12) at the time of the study were excluded. For
simplicity, patients with distant metastases (including those with ‘distant-only recurrence,’
and those with ‘distant and local recurrence’) were collapsed into a single category for the
regression model and compared to patients with a local-only recurrence (Table 3). Adjuvant
therapy did not play a role in recurrence patterns, and this was consistent when either
chemotherapy or radiation was factored into the model. Similarly, SMAD4 did not have any
predictive value. Regional lymph node metastases were significantly associated with distant
metastases, while other conventional pathologic features were not. Table 4 details the lymph
node status according to recurrence pattern. While lymph node metastases were absent in
28% (36 of 127) of the total cohort, 60% (9 of 15 patients) of the patients in the local-only
group were free of lymph node metastases (Fisher's exact= 0.04, Table 4).
SMAD4 has been implicated as a prognostic marker, and therefore we evaluated the
biomarker's ability to distinguish short- and long-term survivors in the present cohort. Loss
of SMAD4 was observed in 22 of 56 patients (39%) in the short survivor group, as
compared to 18 of 71 patients (25%) in the long survivor group (p=0.12). A multivariate
regression analysis was performed which included conventional pathologic features and
adjuvant treatment. In this model SMAD4 did not reach statistical significance: SMAD4,
odds ratio (OR)=0.5, p=0.15; positive lymph nodes, OR=4.5, p=0.005; positive resection
margin, OR=1.5, p=0.5; poor differentiation, OR=2.8, p=0.02; tumor more than 3 cm,
OR=2.2, p=0.07; adjuvant treatment, OR=0.3, p=0.02.
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SMAD4 expression was scored by a second pathologist to test inter-rater reliability. There
was substantial agreement between pathologists, with 83% agreement and κ=0.6114
(p<0.0001). The entire analysis was repeated using scores from the second pathologist, and
none of the findings changed (data not included).
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Discussion
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SMAD4 is a tumor suppressor gene involved in TGFβ signaling [12], and is inactivated by
homozygous deletions or somatic mutations in over 50% of sporadic pancreatic
adenocarcinomas [13-15]. In this study, primary tumor specimens from a large number of
patients (n=127) with resected ductal adenocarcinoma of the pancreas were examined for
SMAD4 expression and analyzed with respect to pattern of failure. SMAD4 expression was
absent in approximately 1/3 of pancreatic adenocarcinomas, regardless of the survival
outcome, general pattern of failure, or the specific organ site of recurrence. We believe this
is an important finding in the context of two recent studies which observed that intact
SMAD4 expression was associated with a local recurrence, while absent SMAD4 expression
was associated with distant metastases [9, 10]. While we cannot definitively account for the
different conclusions from our study, the most likely explanation relates to differences in
patient selection.
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Iacobuzio et al. profiled the pattern of failure in 76 autopsies performed on patients who
died from pancreatic adenocarcinoma [10]. Less than 1/3 of the patients presented with
resectable disease (Stage I or II), while the remaining patients presented with stage III (24%)
or stage IV (47%) disease. In addition, 10% of patients had rare variants of nonconventional ductal (tubular) adenocarcinoma. The authors examined SMAD4 expression in
tumors of 65 of the autopsy specimens, and observed loss of SMAD4 in 41 (63%) of the
samples. Just 2 of 9 autopsies that exhibited a pattern of locally advanced pancreatic cancer
without metastases had tumors with loss of SMAD4 (22%). However, 16 of 22 patients with
numerous metastases had tumors that lacked SMAD4 expression (78%). SMAD4 expression
status was then analyzed in individuals with intermediate phenotypes, but who had
recurrence patterns that could nonetheless be classified as either locally destructive or
locally confined. Again, a statistically significant association between the recurrence pattern
and SMAD4 expression status was noted when all 65 individuals were analyzed together
(p=0.007).
A recent phase two trial examining chemotherapy followed by chemoradiation in patients
with locally unresectable pancreatic cancer included a biological correlative component that
examined SMAD4 expression in cytologic samples and analyzed the findings with respect to
disease pattern [9]. Out of 41 patients with available tissue, 15 (37%) recurred in a local
predominant pattern, 14 (34%) with distant metastases, and 8 (20%) with an indeterminate
pattern. Out of 15 patients with intact SMAD4 expression in their tumors, 11 (73%) of them
progressed locally. On the other hand, 10 of the 14 (71%) patients with loss of SMAD4 in
their tumors recurred predominantly at distant sites (p=0.016).
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An important difference between the two aforementioned studies and the present one is that
the entire cohort of patients in the current one underwent a pancreatic resection. In contrast,
only 29% of patients included in the autopsy study and 10% in the study of locally advanced
pancreatic cancer underwent resection. While resection is not curative in the majority of
patients, the intervention usually renders patients free of gross disease at the primary site,
and in doing so, can have a profound impact on the recurrence pattern of the cancer. It is
also possible that the cancers examined from the present series have a slightly different
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biologic behavior as a group, since they generally presented at an earlier stage (AJCC 7th
Ed/TNM stages I and II) than the cancers included in the previous SMAD4 studies
(generally stages III or IV). Other distinguishing qualities of the present series include the
relatively large samples size, the use of surgical pathology (as opposed to cytology) in all
cases, and the uniformity with respect to tumor type (all ductal adenocarcinoma). Taken
together, we believe that the findings herein comprise the most accurate and applicable
published dataset of SMAD4 expression in surgical patients with pancreatic
adenocarcinoma.
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While previous studies classified recurrence patterns according to whether or not the tumor
was locally destructive or locally predominant, we felt that a more clinically relevant
classification scheme should be based on whether or not the recurrence was localized in the
retroperitoneum. While this classification difference is largely semantic, a retroperitoneal
recurrence, either in the resection bed or in the regional lymph nodes, is a local one. The
recurrence can be treated by radiation with minimal acute toxicity to the intestinal tract. On
the contrary, the therapeutic window with radiation therapy may be smaller for locally
destructive tumors in other sites in the abdomen, such as the small bowel mesentery. Along
these lines, recurrences limited to the retroperitoneum may be reduced, in theory, by
adjuvant radiation.
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Pathologic features of the tumor and treatment were included in a multivariate model to
determine if these key variables influenced the study findings. SMAD4 failed to predict
recurrence pattern in the multivariate model. Similarly radiation, chemotherapy, resection
margin status, histologic grade, and tumor size were not associated with the pattern of
failure. However, the absence of lymph node metastases in the resection specimen was
associated with a local-only recurrence, while lymph node metastases predicted systemic
recurrence. Patients with lymph node metastases in fact had an adjusted odds ratio for a
systemic recurrence more than five-fold greater than patients without lymph node spread.
Based on these findings, oncologists who selectively recommend adjuvant chemoradiation
for ductal adenocarcinoma of the pancreas according to tumor related characteristics should
give particular consideration for cancers without lymph node metastases. On the other hand,
due to the high rate of systemic recurrences, resected patients with lymph nodes metastases
may be less likely to benefit from adjuvant radiation therapy. In the present study, 9 patients
without lymph node metastases in their resection specimen had a local-only recurrence. Of
these patients, 6 (66%) did not receive adjuvant radiation therapy and in retrospect, may
have benefited from additional local treatment.
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Controversy exists in the literature regarding SMAD4 as a prognostic marker, in addition to
a marker of recurrence pattern. For instance, SMAD4 expression was determined by direct
sequencing in 89 patients with resected pancreatic ductal adenocarcinoma and inactivation
was associated with worse survival (14 vs. 12 months, p=0.006) [16]. Interestingly, an older
report described a population of 129 patients with pancreatic ductal adenocarcinoma (51
who underwent resections), in which loss of SMAD4 was associated with improved survival
(9 vs. 6 months, p=0.009), resectability, and earlier stage [17]. The differences disappeared
in a multivariate model adjusting for pathologic features. In the present study, there is a
trend towards worse survival with loss of SMAD4, which did not reach statistical
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significance. Additional findings in the multivariate analysis were consistent with our
overall experience of more than 1000 PDAs; lymph node metastases and poor histologic
grade were statistically significant predictors of survival, while resection margin was not
[18]. The consistency between the larger dataset and the present study with regards to
standard pathologic features provides reassurance that the smaller group is representative in
at least this one very important aspect. The present data, combined with prior studies,
suggest that loss of SMAD4 may be associated with unfavorable prognosis in pancreatic
cancer, although the connection is not robust.
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The present study has certain limitations based on the study design that deserve mention. In
contrast to the autopsy study, the ability to determine recurrence clinically and from imaging
is difficult. The absence of a detected recurrence, local or distant, does not confirm the
absence of disease. Furthermore, patients were included from two ends of the survival
spectrum, and therefore we are required to extrapolate these results for patients with
intermediate survivals. Finally, treatment regimens were variable. However, this last point
can be viewed as an important requirement for a reliable biomarker to gain widespread
acceptance, as these data reflect real world treatment patterns.
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Figure 1.
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SMAD4 immunohistochemistry in representative cores of pancreatic ductal
adenocarcinoma. Neoplastic epithelial cells lack SMAD4 expression in contrast to
nonneoplastic stromal cells in a) and b). SMAD4 expression is observed in cancer cells as
well as the non-neoplastic stromal cells in c) and d).
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Figure 2.
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Percentage of patients (total, n=127) who recurred at the indicated sites. NED, no evidence
of disease.
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Recurrence pattern, stratified by tumor biology (n=127)
Short survival, <12 months, n=56

Long survival, >30 months, n=71

All patients, n=127

2 (4%)

13 (18%)

15 (12%)

Distant recurrence only

21 (38%)

21 (30%)

42 (33%)

Local and distant recurrence

33 (59%)

25 (35%)

58 (46%)

0 (0)

12 (17%)

12 (9%)

Local recurrence only

No recurrence

Percentages are with respect to the specified cohort (i.e. each column)
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Recurrence pattern and SMAD4 expression status (n=127)
SMAD4 Loss

SMAD4 Expression

40 (31.5%)

87 (68.5%)

Local recurrence only

4 (27%)

11 (73%)

Distant recurrence only

14 (33%)

28 (67%)

Local and distant recurrence

19 (33%)

39 (67%)

No recurrence

3 (25%)

9 (75%)

Total

Percentages are with respect to recurrence pattern (i.e. each row)
SMAD4 loss vs. SMAD4 expression, Fisher's exact, p=0.9
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Table 3

Author Manuscript

Multivariate regression model of recurrence pattern: predictors of distant metastases (n=115)
N (%)

Odds Ratio

P value

43 (39%)

1.2

0.8

SMAD4

37 (32%)

1.2

0.8

Positive lymph nodes

81 (70%)

6.0

0.001

Positive resection margin

16 (14%)

1.3

0.8

Poor differentiation

39 (34%)

1.1

0.9

Size > 3 cm

73(64%)

1.9

0.3

Adjuvant therapy

The results are consistent when adjuvant chemotherapy or radiation are substituted for adjuvant therapy. The regressions estimate the risk of distant
metastases. Patients in the 'distant recurrence only' category are grouped with patients who had both 'local and distant recurrence.' Patients with no
evidence of disease (n=12) were excluded from the regression model, as many will recur at some point in the future.
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Table 4

Author Manuscript

Recurrence by site and lymph node status (n=127)
Negative Lymph Nodes, n=36

Positive Lymph Nodes N=91

9 (60%)

6 (40%)

Distant recurrence only

9 (21%)

33 (79%)

Local and distant recurrence

16 (28%)

42 (72%)

2 (17)

10 (83%)

Local recurrence only

No recurrence

Percentages are with regards to recurrence pattern (i.e. each row) P=0.04
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